Hemophilia Market Snapshot: Is There Enough Innovation For Patients To Switch?
A cautious patient population with long memories could thwart the potential of new hemophilia A treatments, even as the market leaders promise Wall Street that switching patients will be no problem.
You may also be interested in...
Fitusiran's mechanism of reducing antithrombin levels could apply to all hemophilia patients, as well as those with other rare bleeding disorders. Reducing antithrombin increases thrombin levels and helps to increase normal clotting.
RNAi pioneer is getting closer to market with NDA filing in amyloidosis expected in 2017, but ample competition is coming along, albeit far behind.
Company will prioritize potential Kogenate successor Kovaltry for hemophilia A, and delay filing of BAY 94-9027.